Sanofi-Aventis Wins European Approval for Diabetes Drug
Posted on: Friday, 25 July 2008, 12:01 CDT
Sanofi-Aventis has announced that the European Commission approved Apidra, a rapid-acting insulin analog, for the control of hyperglycemia in adolescents and children with diabetes mellitus.
The approval of Apidra for pediatric use provides children with the option of using Apidra as part of their overall diabetes treatment plan, usually in combination with basal insulin.
The approval is based upon review of a 26-week, Phase III, open-label, active control study of Apidra in comparison with Humalog (both administered premeal) in 572 children and adolescents with type 1 diabetes. Apidra can also be used alone in insulin infusion pump therapy for blood sugar control.
Riccardo Perfetti, senior medical director of diabetes-metabolism franchise at Sanofi-Aventis, said: "Now the rapid-acting insulin analog Apidra will be available to children six years and older with diabetes, and we hope it will offer them an effective treatment of choice for their overall diabetes therapy."
Source: Datamonitor
Related Articles
- Monotherapy BYETTA(R) (Exenatide) Injection Study Results Presented at ADA 2008 Showed Adults With Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
- Five Steps to Reversing Type 2 Diabetes and Insulin Resistance
- Sirtris Pharmaceuticals to Present at Keystone Symposia's Diabetes Mellitus, Insulin Action and Resistance Conference
- FDA Approves JANUMET(TM) for Type 2 Diabetes, Offering Powerful Glucose Control of a DPP-4 Inhibitor and Metformin in a Single Tablet
- Diabetics Getting Better at Controlling Their Blood Sugar
- National Study Reveals Doubling in Type 2 Diabetes Prescriptions Among Children
- Obesity Blamed for Diabetes in 1,000 Children
- Waist Girth Predicts Diabetes Risk in Children
- FDA Panel Endorses a New Pill for Type 2 Diabetics ; Non-Insulin Treatment is for Condition That is Most Often Seen in Overweight Adults
- CDC Issues Diabetes Warning for Children
 |
 |
User Comments (0)
RSS Feeds